1. Colangiocarcinoma
Sandra Milena Acevedo Rueda
MD Residente 2do año
Medicina Interna UNAB

2. Colangiocarcinoma
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748
El término “colangiocarcinoma” incluye los cánceres de todos los conductos biliares
(intrahepático, perihiliar y extrahepático distal)
20% son intrahepáticos
50-60% son perihiliares, envuelven la bifurcación de los conductos

3. Colangiocarcinoma
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition
of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol
2010;17:1471e4.
BismutheCorlette classification of biliary
strictures

4. Colangiocarcinoma
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748
-Segundo tumor más frecuente – hepático
-1500 muertes en UK cada año
-Factores de riesgo 30% casos
-Colangitis esclerosante primaria (Enf. inflamatoria intestinal)

5. Colangiocarcinoma
Established risk factors for cholangiocarcinoma (CC)
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748

6. Colangiocarcinoma
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748
-Cirrosis
-Hepatitis B, C
-Diabetes
-Hígado graso
-Alcohol
-Cigarrillo
-Toxinas: Nitrosaminas, dioxinas, cloruro vinil
FR Menos comunes

7. Colangiocarcinoma
Main macroscopic types of cholangiocarcinoma (CC)
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748

8. Colangiocarcinoma
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition
of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol
2010;17:1471e4.
90% son Adenocarcinomas

9. Colangiocarcinoma
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748
 Características clínicas
 Laboratorios
 Marcadores tumorales
 Inmunohistoquímica!

10. Colangiocarcinoma
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748
Inactivación de genes supresores tumorales
p53, Smad-4, bcl-2 y p16
Mutaciones de oncogenes K-ras, p53, c-erbB-2 y
c-neu

11. Colangiocarcinoma
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition
of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol
2010;17:1471e4.
IgG4 cholangiopathy
should be excluded in suspected cases of
CC by testing for increased IgG4 in serum
and biliary samples

12. Colangiocarcinoma
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748
 Imágenes
Ultrasonografía
TAC espiral o alta resolución
RMN

13. Colangiocarcinoma
MRCP had superior sensitivity (96%), specificity
(85%) and accuracy (91%) compared with ERCP
(80%, 75% and 78%, respectively) for differentiating
between CC and benign strictures

14. Colangiocarcinoma
Khan SA, Davidson BR, Goldin RD, et al. Gut (2012).
doi:10.1136/gutjnl-2011-301748

15. Asian Pac J Cancer Prev. 2013;14(3):1623-7.
Factors affecting survival time
of cholangiocarcinoma patients: a
prospective study in northeast Thailand.
Woradet S, Promthet S, Songserm N, Parkin DM
Colangiocarcinoma

16. Ann Clin Lab Sci. 2013 Spring;43(2):195-210.
Cholangiocarcinoma: risk factors,
environmental influences and oncogenesis.
Al-Bahrani R, Abuetabh Y, Zeitouni N, Sergi C.
Colangiocarcinoma

17. World J Gastroenterol. 2013 Apr
28;19(16):2456-65.
Annexin A1: A new immunohistological marker
of cholangiocarcinoma.
Hongsrichan N, Rucksaken R, Chamgramol
Y, Pinlaor P, Techasen A, Yongvanit
P, Khuntikeo N, Pairojkul C, Pinlaor S.
Colangiocarcinoma

18. Gracias!